| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:BMS-823778
CAS:1140897-32-0
Purity:99.00% Package:1mg;5mg;10mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:BMS-823778
CAS:1140897-32-0
Purity:99.39% Package:1mg/RMB 1980;5mg/RMB 4920;10mg/RMB 7130
|
BMS-823778 free base manufacturers
- BMS-823778
-
- $176.00 / 1mg
-
2025-11-11
- CAS:1140897-32-0
- Min. Order:
- Purity: 99.75%
- Supply Ability: 10g
|
| | BMS-823778 free base Basic information |
| Product Name: | BMS-823778 free base | | Synonyms: | BMS-823778 free base;1,2,4-Triazolo[4,3-a]pyridine-8-methanol, 3-[1-(4-chlorophenyl)cyclopropyl]-α,α-dimethyl- | | CAS: | 1140897-32-0 | | MF: | C18H18ClN3O | | MW: | 327.81 | | EINECS: | | | Product Categories: | | | Mol File: | 1140897-32-0.mol |  |
| | BMS-823778 free base Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | pka | 12.86±0.29(Predicted) |
| | BMS-823778 free base Usage And Synthesis |
| Uses | BMS-823778 was developed as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 to inhibit type 2 diabetes[1]. | | References | [1] Maxwell BD, et al. The syntheses of [(14) C]BMS-823778 for use in a human ADME clinical study and of [(13) CD3 (13) CD2 ]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite. J Labelled Comp Radiopharm. 2016 May 30;59(6):255-9. DOI:10.1002/jlcr.3383 |
| | BMS-823778 free base Preparation Products And Raw materials |
|